Disease landscape
Ovarian Cancer
Moderate constraints in access to ovarian cancer treatment and diagnosis in Visegrád (V4) countries have been revealed in the GAP score analysis. The results vary across the countries with the difference between the highest and the lowest score by as much as 22 points. The main cause of unsatisfactory V4 performance is limited access to the registered drugs in the V4 countries which translates into low PARP inhibitors uptake in some countries.
Cross-Country
General GAP for Ovarian Cancer
Compliance with guidelines
Three ovarian cancer drugs had a positive recommendation in the clinical practice guidelines. Only 2 of them are available to OC patients in each of the V4 countries resulting in 67% of possible treatment compliance with the guidelines in the region.
From registration to reimbursement
Population burden
DALY* - Rate per 100k
*disability adjusted life-years
Target population
PARP inhibitors
Drug access
Number of patients treated (2022)
Drug access
Population treated (%)
Main issues
- The average time to reimbursement for ovarian cancer drugs in the V4 countries is 5.5 years. The difference between the shortest and the longest mean time to reimbursement among the coutriess is over 4.7 years.
- Overall, about half of the V4 ovarian cancer patients, potentially suitable for the PARP inhibitors, were actually treated with one of these drugs. Treatment coverage, however, varies greatly between the V4 countries from 15% in Slovakia through 37% in Hungary to 72% in Poland and Czechia.
- DALY (disability adjusted life-years) burden in most V4 countries is far above the European Union average. The only exception is Slovakia with the most recent DALY burden being exactly at the average EU level.
Project
We measured the gap in innovative drug access and diagnostics in selected therapeutic areas in the Visegrád (V4) countries (Poland, Hungary, Czechia and Slovakia).